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Three-part clinical question:
Patients: Adult patients suffering in-hospital, vasopressor-requiring cardiac arrest. Intervention and comparison: For the first five cycles of cardiopulmonary resuscitation (CPR), patients received either epinephrine/adrenaline (1 mg) with vasopressin (20 U) or epinephrine/adrenaline with saline placebo. Patients receiving vasopressin were also given a single dose of methylprednisolone (40 mg) during the first cycle, whilst controls received saline placebo. Patients with post-resuscitation shock at 4 h received stress-dose hydrocortisone (300 mg/d for 4 7 days and gradual taper) in the VSE (vasopressor-steroid-epinephrine) group or saline placebo in controls. Outcomes: Return of spontaneous circulation (ROSC) for 20 min or longer, and survival to hospital discharge with favourable neurological recovery (Glasgow-Pittsburgh Cerebral Performance Category [GPCPC] score of 1 or 2).
Study design:
A multi-centre prospective, randomised, double-blind placebo-controlled trial.
Study patients:
Eligible: Adult patients suffering in-hospital, vasopressor-requiring cardiac arrest resuscitated according to European Resuscitation Council guidelines (2005) . Included: 268 patients. Exclusion: Age younger than 18 years, terminal illness (i.e. life expectancy < 6 weeks) or do-not-resuscitate status, cardiac arrest due to exsanguination, cardiac arrest before hospital admission, treatment with intravenous steroids before arrest, previous enrolment in or exclusion from the same study.
Intervention group: 130 patients (146 randomised; 16 did not receive intervention as ROSC confirmed before study drug administered). Epinephrine/adrenaline (1 mg) plus vasopressin (20 IU), in pre-filled syringes, was administered between each cycle of CPR (cycle duration 3 min). Methylprednisolone (40 mg) was administered separately during the first cycle of CPR. Patients with post-resuscitation shock (mean arterial pressure, MAP, < 70) at 4 h received hydrocortisone in 100 ml of normal saline once daily (300 mg until the day of vasopressor cessation or day 8 post-arrest, and then dose reduced by 100 mg daily).
Control group: 138 patients (154 randomised; 16 did not receive intervention). Epinephrine/adrenaline (1 mg) plus saline placebo between each cycle of CPR, with saline placebo instead of methylprednislone during the first cycle of CPR. Patients with post-resuscitation shock at 4 h received 100 ml of normal saline once daily (any prescription of openlabel hydrocortisone cancelled the experimental treatment).
Results:
Heterogeneity between the three centres was low for ROSC and neurologically favourable survival (I 2 ¼ 0.16 and 0, respectively).
The VSE group had higher probability of ROSC for 20 min or longer and was more likely to survive to hospital discharge with a favourable neurological recovery ( Table 1) .
Compared with controls, VSE patients had significantly more neurological and renal failure-free days and more ventilator-free days ( This was appropriately powered for the primary outcomes (based on estimated survival benefit from 4% to 15%; the preliminary study showed a survival benefit for favourable neurological recovery of 15% compared with 4% in controls), and although there was more than one primary outcome -increasing the chances of a single positive result -both were positive. However, as the VSE and post-arrest shock/stressdose hydrocortisone protocol was applied as a bundle, it is not possible to quantify the effect of any individual component on survival to discharge with favourable neurological recovery. 4. Did results get omitted, and why? No.
Did the authors suggest areas of further research?
Yes. The specific effect of post-arrest hydrocortisone alone on neurologically intact survival. 1 Although studies looking at the effect of corticosteroids on organ dysfunction in sepsis suggest potential for benefit in the post-arrest syndrome, this and the preliminary study by the same group are the only human randomised trials investigating corticosteroid use after ROSC. Further work, possibly using multi-arm intervention groups, is required to differentiate the relative effects of each part of the VSE bindle on survival. 6. Did they make any recommendations based on the results and were they appropriate? No. No specific recommendations were made. 7. Is the study relevant to my clinical practice? Yes. But only in selected patients (i.e. adult in-hospital cardiac arrest and refractory post-resuscitation shock at 4 h). Notably, there were no recorded defibrillations in the Table 3 . Neurological outcome in survivors still alive at 4 h with post-resuscitation shock; defined as new post-arrest circulatory failure or post-arrest need for 50% or greater increase in any vasopressor/inotropic support targeted to MAP > 70 mmHg.
Outcome
Time Key VSE group received stress-dose hydrocortisone and controls received saline placebo. MAP: mean arterial pressure; CER: control event rate; EER: experimental event rate; RRR: relative risk reduction; NNT: number needed to treat; ARR: absolute risk reduction. Neurorological failure-free days a 0 (0-8); 58 0 (0-0); 58 0.005 Renal failure-free days b 2 (0-40); 60 0 (0-2); 60 0.009 Ventilator-free days 0 (0-11); 60 0 (0-0); 58 0.03 
